FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116735240> ?p ?o ?g. }

• W2116735240 abstract "This thesis describes the pharmacokinetics of azithromycin in cystic fibrosis (CF) patients during maintenance therapy, azithromycin drug-drug interactions and the effects of long term use of azithromycin on pulmonary function and microbial resistance. We studied pharmacokinetic parameters of 500 mg azithromycin per day during maintenance (chronic) therapy in adult CF patients. The t1/2 was > 7 d in blood and in isolated PMNs. On average, the concentration in PMNs was 2100 times the concentration in plasma 24 h after dosing azithromycin and 70% of azithromycin in blood was incorporated in or bound to PMNs. Elevated concentrations were found in sputum (12 to 53 mg/L). The long t ½ indicated that a less frequent dosing scheme could be feasible. We studied pharmacokinetics and sputum penetration of azithromycin in CF patients after a change from daily dosing of azithromycin to a once weekly dosing scheme. The weekly dose was reduced with a factor 3.5 (500 mg daily vs 1000 mg weekly). This lead to a reduction of AZM exposure by a factor (±SD) of 2.5 (±0.8) in plasma, 2.8 (±0.9) in blood and 2.3 (±1.1) in PMNs and 3.0 (±1.5) in sputum concentration. We concluded that reduction in frequency was feasible and resulted in an approximately linear reduction of azithromycin exposure. In an earlier study, inhibition of the DNA hydrolysing capacity of dornase alfa by azithromycin was reported(Ripoll 1996). We found that in-vitro azithromycin did not inhibit the DNA hydrolysing capacity of dornase alfa at clinically representative sputum concentrations. These data combined with the data found in clinical trials do, in our opinion, not restrict the concurrent use of dornase alfa and azithromycin. We evaluated the long term effect of azithromycin on pulmonary function by comparing patients infected with P. aeruginosa (using azithromycin) to a non-pseudomonas infected cohort (not using azithromycin). We found an amelioration in pulmonary function in the first year after start of therapy. In the following years a decline in pulmonary function was found. The rate of decline of pulmonary function however, was comparable in both groups.Comparing 1997 (the last year before introduction of azithromycin maintenance therapy) and 2007 we observed a decrease in incidence of staphylococcal infections and an marked increase, from 10% to 85%, in macrolide resistance of S. aureus. This finding has been documented before in cystic fibrosis patients in Rotterdam (Phaff 2006), and has to be taken into account when azithromicin maintenance therapy is started.Based on the pharmacokinetic data found in our study and on a literature search of available clinical trials we propose a dosing scheme with 4 weight groups and a dose level between 20 and 33 mg/kg/week in pediatric and adult CF patients.The comparable rate of decline in P. aeruginosa infected and uninfected patients is a valuable achievement of current CF treatment, including azithromycin maintenance therapy, but cannot be contributed to azithromycin alone, since, in the timeframe we analyzed, also other anti Pseudomonas therapies have been introduced" @default.
• W2116735240 created "2016-06-24" @default.
• W2116735240 creator A5010547356 @default.
• W2116735240 date "2012-04-12" @default.
• W2116735240 modified "2023-09-25" @default.
• W2116735240 title "Azithromycin in cystic fibrosis : pharmacokinetic and therapeutic aspects of maintenance therapy" @default.
• W2116735240 cites W1491928898 @default.
• W2116735240 cites W1589498660 @default.
• W2116735240 cites W1896897128 @default.
• W2116735240 cites W1975789772 @default.
• W2116735240 cites W1983801292 @default.
• W2116735240 cites W1999136766 @default.
• W2116735240 cites W2001822386 @default.
• W2116735240 cites W2013703185 @default.
• W2116735240 cites W2016283787 @default.
• W2116735240 cites W2023174165 @default.
• W2116735240 cites W2027086510 @default.
• W2116735240 cites W2027845120 @default.
• W2116735240 cites W2034930650 @default.
• W2116735240 cites W2051910160 @default.
• W2116735240 cites W2052616397 @default.
• W2116735240 cites W2053444103 @default.
• W2116735240 cites W2078851114 @default.
• W2116735240 cites W2081524758 @default.
• W2116735240 cites W2090648579 @default.
• W2116735240 cites W2092521976 @default.
• W2116735240 cites W2093234322 @default.
• W2116735240 cites W2100151025 @default.
• W2116735240 cites W2102904779 @default.
• W2116735240 cites W2112137575 @default.
• W2116735240 cites W2122915830 @default.
• W2116735240 cites W2123178771 @default.
• W2116735240 cites W2133441630 @default.
• W2116735240 cites W2138872715 @default.
• W2116735240 cites W2149276285 @default.
• W2116735240 cites W2153267334 @default.
• W2116735240 cites W2155912663 @default.
• W2116735240 cites W2168310137 @default.
• W2116735240 cites W2170351952 @default.
• W2116735240 cites W2185127450 @default.
• W2116735240 cites W2336284588 @default.
• W2116735240 cites W194150669 @default.
• W2116735240 hasPublicationYear "2012" @default.
• W2116735240 type Work @default.
• W2116735240 sameAs 2116735240 @default.
• W2116735240 citedByCount "0" @default.
• W2116735240 crossrefType "dissertation" @default.
• W2116735240 hasAuthorship W2116735240A5010547356 @default.
• W2116735240 hasConcept C112705442 @default.
• W2116735240 hasConcept C126322002 @default.
• W2116735240 hasConcept C142724271 @default.
• W2116735240 hasConcept C2776301714 @default.
• W2116735240 hasConcept C2776938444 @default.
• W2116735240 hasConcept C2777288759 @default.
• W2116735240 hasConcept C2778907293 @default.
• W2116735240 hasConcept C2781069245 @default.
• W2116735240 hasConcept C501593827 @default.
• W2116735240 hasConcept C71924100 @default.
• W2116735240 hasConcept C86803240 @default.
• W2116735240 hasConcept C89423630 @default.
• W2116735240 hasConcept C98274493 @default.
• W2116735240 hasConceptScore W2116735240C112705442 @default.
• W2116735240 hasConceptScore W2116735240C126322002 @default.
• W2116735240 hasConceptScore W2116735240C142724271 @default.
• W2116735240 hasConceptScore W2116735240C2776301714 @default.
• W2116735240 hasConceptScore W2116735240C2776938444 @default.
• W2116735240 hasConceptScore W2116735240C2777288759 @default.
• W2116735240 hasConceptScore W2116735240C2778907293 @default.
• W2116735240 hasConceptScore W2116735240C2781069245 @default.
• W2116735240 hasConceptScore W2116735240C501593827 @default.
• W2116735240 hasConceptScore W2116735240C71924100 @default.
• W2116735240 hasConceptScore W2116735240C86803240 @default.
• W2116735240 hasConceptScore W2116735240C89423630 @default.
• W2116735240 hasConceptScore W2116735240C98274493 @default.
• W2116735240 hasLocation W21167352401 @default.
• W2116735240 hasOpenAccess W2116735240 @default.
• W2116735240 hasPrimaryLocation W21167352401 @default.
• W2116735240 hasRelatedWork W199806143 @default.
• W2116735240 hasRelatedWork W2027266089 @default.
• W2116735240 hasRelatedWork W2029002658 @default.
• W2116735240 hasRelatedWork W2036276557 @default.
• W2116735240 hasRelatedWork W2120806423 @default.
• W2116735240 hasRelatedWork W2161185513 @default.
• W2116735240 hasRelatedWork W2166507959 @default.
• W2116735240 hasRelatedWork W2257048501 @default.
• W2116735240 hasRelatedWork W2281672386 @default.
• W2116735240 hasRelatedWork W2354679576 @default.
• W2116735240 hasRelatedWork W2355148684 @default.
• W2116735240 hasRelatedWork W2355274318 @default.
• W2116735240 hasRelatedWork W2355917415 @default.
• W2116735240 hasRelatedWork W2371062103 @default.
• W2116735240 hasRelatedWork W2376245631 @default.
• W2116735240 hasRelatedWork W2404079246 @default.
• W2116735240 hasRelatedWork W2405095283 @default.
• W2116735240 hasRelatedWork W2922400738 @default.
• W2116735240 hasRelatedWork W3210162847 @default.
• W2116735240 hasRelatedWork W653894113 @default.
• W2116735240 hasVolume "3" @default.
• W2116735240 isParatext "false" @default.
• W2116735240 isRetracted "false" @default.

• next